In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
APX001 is the prodrug of APX001A, which is a first-in-class small molecule with a unique mechanism of action that inhibits the fungal enzyme Gwt1 in the glycosylphosphatidylinositol (GPI) biosynthesis pathway. The goal of the present study was to determine which pharmacokinetic/pharmacodynamic (PK/PD) index and magnitude best correlated with efficacy in the murine disseminated candidiasis model for Candida albicans ( n = 5), C. glabrata ( n = 5), and C. auris ( n = 4). MIC values ranged from 0.002 to 0.03 mg/liter for C. albicans , from 0.008 to 0.06 mg/liter for C. glabrata , and from 0.004 to 0.03 mg/liter for C. auris . Plasma APX001A pharmacokinetic measurements were performed in mice after oral administration of 4, 16, 64, and 256 mg/kg of body weight APX001. Single-dose pharmacokinetic studies exhibited maximum plasma concentration ( C max ) values of 0.46 to 15.6 mg/liter, area under the concentration-time curve (AUC) from time zero to infinity (AUC 0–inf ) values of 0.87 to 70.0 mg · h/liter, and half-lives of 1.40 to 2.75 h. A neutropenic murine disseminated candidiasis model was utilized for all treatment studies, and drug dosing was by the oral route. Dose fractionation was performed against C. albicans K1, with total doses ranging from 4 to 1,024 mg/kg/day of APX001 fractionated into regimens of dosing every 3, 6, 8, and 12 h for a 24-h treatment duration. Nonlinear regression analysis was used to determine which PK/PD index best correlated with efficacy on the basis of the reduction in the number of CFU/kidney at 24 h. The 24-h free-drug AUC/MIC ratio ( f AUC 0–24 /MIC) was the PK/PD index that best correlated with efficacy (coefficient of determination [ R 2 ] = 0.88). Treatment studies with the remaining strains utilized regimens of 1 to 256 mg/kg of APX001 administered every 6 h for a 24-h duration with C. albicans and a 96-h study duration with C. glabrata and C. auris . The dose required to achieve 50% of the maximum effect (ED 50 ) and stasis f AUC/MIC targets were as follows: for C. albicans , 3.67 ± 3.19 and 20.60 ± 6.50, respectively; for C. glabrata , 0.38 ± 0.21 and 1.31 ± 0.27, respectively; and for C. auris , 7.14 ± 4.54 and 14.67 ± 8.30, respectively. The present studies demonstrated in vitro and in vivo APX001A and APX001 potency, respectively, against C. albicans , C. glabrata , and C. auris. These results have potential relevance for clinical dose selection and evaluation of susceptibility breakpoints. The identification of a lower AUC/MIC ratio target for C. glabrata suggests that species-specific susceptibility breakpoints should be explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Broad-spectrum antifungal activity has been observed against pathogenic yeasts and molds, including activity against resistant strains (16–18).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 28 · Cited by 68
Research works printed but not linked: 1
- Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Approved standard M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
Metadata
- Authors
- Zhao, M., Lepak, A. J., VanScoy, B., Bader, J. C., Marchillo, K., Vanhecker, J., Ambrose, P. G., & Andes, D. R.
- Affiliations
- University of Wisconsin–Madison (US)
- Institute for Clinical Pharmacodynamics (United States) (US)
- William S. Middleton Memorial Veterans Hospital (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2018-04
- Volume
- 62
- Issue
- 4
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC5913987
- OpenAlex
- W2792314560
- Cited by
- 68
- References
- 28
- Citations by year
- 2026: 6 · 2025: 1 · 2024: 3 · 2023: 6 · 2022: 8 · 2021: 10 · 2020: 14 · 2019: 11 · 2018: 9
- FWCI
- 8.31
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amplyx
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- prodrugs, Candida albicans, Candida glabrata, Candida auris, systemic candidiasis, neutropenia, pharmacokinetics, pharmacodynamics, glycosylphosphatidylinositol biosynthesis, antifungal agents
- MeSH terms
- Animals, Antifungal Agents, Candida, Candida albicans, Candidiasis, Disease Models, Animal, Female, Microbial Sensitivity Tests, Candida glabrata, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model. https://app.cochat.ai/papers/10.1128/aac.02542-17
- The paper
- Zhao, M., Lepak, A. J., VanScoy, B., Bader, J. C., Marchillo, K., Vanhecker, J., Ambrose, P. G., & Andes, D. R. (2018). In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.02542-17
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.